

Please replace the paragraph at page 24, lines 19 through 25 with the following two paragraphs:

Preparation of poly(hexamethylene biscyano guanidine-alt-1,3-aminoguanidine) (XXVII).

Hexamethylene biscyano guanidine (4.00 mmols, 1.00 g) and 1,3-aminoguanidine (4.00 mmols, 0.502 g) were added to a 40 ml vial with a septa-cap followed by 2 equivalents of concentrated HCl. The mixture was heated to 165° C in an oil-bath for 3 h. The resulting orange solid was acidified with 1 eq. concentrated HCl, dissolved in water and purified by centrifugation through a 3K Macrosep filtration membrane.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i).

REMARKS

Information Disclosure Statement

An Information Disclosure Statement (IDS) was filed on October 25, 2002, a Supplemental IDS was filed on December 19, 2002 and a Second Supplemental IDS was filed on March 10, 2003. Entry of the IDS's is respectfully requested.

Amendments to the Specification

The paragraph on page 3 has been amended to correct a minor typographical error. The paragraph on page 24 has been amended to include a hard (carriage) return between lines, and split one paragraph into two paragraphs. No new matter has been added.

10/051,766

-4-

CONCLUSION

If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (978) 341-0036.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Jesse A. Fecker
Jesse A. Fecker
Registration No. 52,883
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133
Dated: 4-9-03

MARKED UP VERSION OF AMENDMENTSSpecification Amendments Under 37 C.F.R. § 1.121(b)(1)(iii)

Replace the paragraph at page 3, lines 5 through 12 with the below paragraph marked up by way of bracketing and underlining to show the changes relative to the previous version of the paragraph.

This invention relates to the use of polyionenes are effective in treating or preventing oral mucositis in hamsters. For example, the polyionene poly(4,4'-trimethylenebis(1-methylpiperidinium)-alt-octane) (X) was effective in significantly reducing the severity of oral mucositis at a concentration as low as 1.0 mg/mL. This contrasts with chlorhexidine, which is commonly used to treat oral mucositis but was unsuccessful in treating the hamster model at a concentration of 0.5% (v/v). Based on this discovery, methods of treating and/or preventing mucositis in a mammal are disclosed.

Replace the paragraph at page 24, lines 19 through 25 with the below two paragraphs marked up by way of bracketing and underlining to show the changes relative to the previous version of the paragraph.

Preparation of poly(hexamethylene biscyano guanidine-alt-1,3-aminoguanidine) (XXVII). _____
_____ Hexamethylene biscyano guanidine (4.00 mmoles, 1.00 g) and 1,3-aminoguanidine (4.00 mmoles, 0.502 g) were added to a 40 ml vial with a septa-cap followed by 2 equivalents of concentrated HCl. The mixture was heated to 165° C in an oil-bath for 3 h. The resulting orange solid was acidified with 1 eq. concentrated HCl, dissolved in water and purified by centrifugation through a 3K Macrosep filtration membrane.